
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded troche containing ketoprofen, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
FDA-approved products containing ketoprofen are listed in capsule form. No finished ketoprofen product of any kind is listed in troche form.
Bases for this dose form differ, and the base used decides how USP <795> classifies the preparation for beyond-use dating. The date printed on the label is the one to follow.
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID), commonly compounded in topical creams and gels for application to the skin.
Ketoprofen is a nonsteroidal anti-inflammatory drug with analgesic and antipyretic properties. Like other NSAIDs, it reduces the body's production of prostaglandins, chemical messengers involved in pain, swelling and fever; the label notes its mode of action is not fully understood. In the United States, ketoprofen is manufactured as prescription oral capsules and extended-release capsules, indicated for the signs and symptoms of rheumatoid arthritis and osteoarthritis, for the management of pain, and for primary dysmenorrhea.
A prescriber may order ketoprofen compounded when a patient needs a topical form, a strength that is not manufactured, a vehicle free of a specific allergen, or a combination with other active ingredients. Compounded ketoprofen preparations are not FDA-approved and require a prescription.
The ketoprofen capsule label carries a boxed warning: NSAIDs raise the risk of heart attack and stroke, and of serious stomach and intestinal bleeding, ulcers and perforation, which can occur without warning and can be fatal. Older adults are at greater risk. Do not use ketoprofen if aspirin or another NSAID has caused asthma, hives or an allergic reaction, if you are hypersensitive to it, or around heart bypass surgery. Other label warnings include high blood pressure, heart failure, kidney injury, liver injury and serious skin reactions. The label advises limiting NSAID use between about 20 and 30 weeks of pregnancy and avoiding it from about 30 weeks on; MedlinePlus tells patients not to take ketoprofen at or after 20 weeks unless their doctor says to. The label does not recommend ketoprofen for nursing mothers; LactMed states other agents are preferred. Tell your prescriber or pharmacist if you take warfarin, aspirin, lithium, methotrexate, diuretics or ACE inhibitors. European regulators advise keeping skin treated with topical ketoprofen out of sunlight during treatment and for two weeks after, because photosensitivity reactions have been reported. If you develop a rash, stomach pain, black stools, chest pain or shortness of breath, stop use and talk to your prescriber or pharmacist.
Ketoprofen is a propionic acid NSAID supplied as a racemate; only the S enantiomer is pharmacologically active. It inhibits prostaglandin and leukotriene synthesis in animal and in vitro models. After oral dosing, systemic availability is about 90 percent, peak plasma levels occur within 0.5 to 2 hours, protein binding exceeds 99 percent (mainly albumin), metabolism is by glucuronidation, and elimination half-life is about 2 hours, with roughly 80 percent excreted in urine as glucuronide within 24 hours. The acyl-glucuronide can revert to parent drug, relevant in renal insufficiency. A clinical overview of topical ketoprofen 2.5% gel reported serum levels under 1 percent of those after oral dosing.
Labeled indications (ketoprofen capsules, USP): signs and symptoms of rheumatoid arthritis and osteoarthritis, management of pain, and primary dysmenorrhea. Prescribers have ordered compounded topical ketoprofen for localized musculoskeletal pain. A 2011 clinical overview of a European ketoprofen 2.5% gel reported use across a range of musculoskeletal conditions and serum levels under 1 percent of those after oral dosing (Coaccioli, Eur Rev Med Pharmacol Sci 2011). Dosing and application area are per prescriber. Monitor blood pressure, renal function, hepatic enzymes and GI bleeding with systemic exposure; counsel on sun avoidance of treated skin. Interactions of note: ACE inhibitors, diuretics, aspirin, warfarin, lithium, methotrexate and probenecid. Ketoprofen is not a controlled substance.
Wash and dry your hands. Place the troche between your cheek and gum or under your tongue, as your label directs, and let it dissolve. Do not chew or swallow it whole unless told to. Dissolving can take up to 30 minutes. Follow your label about eating or drinking around the dose.
Troches are nonaqueous, so a USP <795> default beyond-use date of up to 180 days usually applies. Store in the closed container in a cool, dry place at room temperature, away from heat so they do not soften, and out of reach of children. Discard after the beyond-use date on the label.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Place 1 troche between cheek and gum and let slowly dissolve